The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events

[1]  Fei-Ting Hsu,et al.  Suppression of EGFR/PKC-δ/NF-κB Signaling Associated With Imipramine-Inhibited Progression of Non-Small Cell Lung Cancer , 2021, Frontiers in Oncology.

[2]  Yan Wang,et al.  Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide , 2021, Journal of cellular and molecular medicine.

[3]  V. Villegas,et al.  Resistance and Overcoming Resistance in Breast Cancer , 2020, Breast cancer.

[4]  Min Jung Kim,et al.  Imipramine Inhibits Migration and Invasion in Metastatic Castration-Resistant Prostate Cancer PC-3 Cells via AKT-Mediated NF-κB Signaling Pathway , 2020, Molecules.

[5]  E. Nice,et al.  Overcoming cancer therapeutic bottleneck by drug repurposing , 2020, Signal Transduction and Targeted Therapy.

[6]  Q. Cheng,et al.  PARP inhibitor resistance: the underlying mechanisms and clinical implications , 2020, Molecular Cancer.

[7]  Hong Ma,et al.  ERα, A Key Target for Cancer Therapy: A Review , 2020, OncoTargets and therapy.

[8]  Fei-Ting Hsu,et al.  Induction of apoptosis through extrinsic/intrinsic pathways and suppression of ERK/NF‐κB signalling participate in anti‐glioblastoma of imipramine , 2020, Journal of cellular and molecular medicine.

[9]  T. Salo,et al.  New role of the antidepressant imipramine as a Fascin1 inhibitor in colorectal cancer cells , 2020, Experimental & Molecular Medicine.

[10]  Carlos L. Arteaga,et al.  Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers , 2019, Breast Cancer Research.

[11]  Jingping Yuan,et al.  The effect of metformin on biomarkers and survivals for breast cancer‐ a systematic review and meta‐analysis of randomized clinical trials , 2019, Pharmacological research.

[12]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[13]  E. Winer,et al.  CDK4/6 inhibition in breast cancer: current practice and future directions , 2018, Therapeutic advances in medical oncology.

[14]  Fangkun Liu,et al.  Repurposing psychiatric drugs as anti-cancer agents. , 2018, Cancer letters.

[15]  P. Kristel,et al.  RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Derek LeRoith,et al.  Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. , 2015, Physiological reviews.

[17]  E. Plimack,et al.  Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors , 2015, Investigational New Drugs.

[18]  T. Hillhouse,et al.  A brief history of the development of antidepressant drugs: from monoamines to glutamate. , 2015, Experimental and clinical psychopharmacology.

[19]  M. Pollak.  Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment , 2014, Nature Medicine.

[20]  C. Caldon,et al.  Estrogen Signaling and the DNA Damage Response in Hormone Dependent Breast Cancers , 2014, Front. Oncol..

[21]  A. Butte,et al.  A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. , 2013, Cancer discovery.

[22]  Jan Koster,et al.  FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. , 2013, Cancer research.

[23]  Shankar Balasubramanian,et al.  Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells , 2013, Genome Biology.

[24]  A. Pertsemlidis,et al.  Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization , 2012, PloS one.

[25]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[26]  J. Game,et al.  Inhibiting homologous recombination for cancer therapy , 2012, Cancer biology & therapy.

[27]  Jeremy M. Stark,et al.  I-SceI-based assays to examine distinct repair outcomes of mammalian chromosomal double strand breaks. , 2012, Methods in molecular biology.

[28]  Philip Machanick,et al.  MEME-ChIP: motif analysis of large DNA datasets , 2011, Bioinform..

[29]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[30]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[31]  A. Hsu,et al.  Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. , 2008, Clinical journal of oncology nursing.

[32]  Nihal Ahmad,et al.  Dose translation from animal to human studies revisited , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  Mathieu Lupien,et al.  CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1. , 2008, Cancer research.

[34]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[35]  Youping Deng,et al.  GeneVenn - A web application for comparing gene lists using Venn diagrams , 2007, Bioinformation.

[36]  T. Mak,et al.  FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal , 2006, The Journal of experimental medicine.

[37]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Coombes,et al.  FoxO3a Transcriptional Regulation of Bim Controls Apoptosis in Paclitaxel-treated Breast Cancer Cell Lines* , 2003, Journal of Biological Chemistry.

[39]  M. Mandal,et al.  Etk/Bmx Tyrosine Kinase Activates Pak1 and Regulates Tumorigenicity of Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[40]  S. Safe,et al.  Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. , 1999, Molecular endocrinology.